Wealthfront Advisers LLC Grows Position in Zoetis Inc. $ZTS

Wealthfront Advisers LLC increased its position in Zoetis Inc. (NYSE:ZTS) by 54.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 37,220 shares of the company’s stock after purchasing an additional 13,097 shares during the period. Wealthfront Advisers LLC’s holdings in Zoetis were worth $5,446,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. Halbert Hargrove Global Advisors LLC lifted its position in Zoetis by 496.6% during the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after acquiring an additional 144 shares during the period. NewSquare Capital LLC increased its stake in shares of Zoetis by 69.1% during the second quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock valued at $32,000 after purchasing an additional 85 shares in the last quarter. Financial Consulate Inc. bought a new position in Zoetis during the 3rd quarter valued at approximately $39,000. SJS Investment Consulting Inc. raised its stake in Zoetis by 1,606.3% during the third quarter. SJS Investment Consulting Inc. now owns 273 shares of the company’s stock valued at $40,000 after buying an additional 257 shares during the last quarter. Finally, TruNorth Capital Management LLC purchased a new position in Zoetis during the third quarter valued at $42,000. Institutional investors own 92.80% of the company’s stock.

Zoetis News Roundup

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Q4 results beat consensus — adjusted EPS $1.48 vs. $1.40 est. and revenue $2.39B vs. $2.36B est.; the company raised FY‑2026 guidance to $7.00–$7.10 EPS and $9.8–$10.0B revenue, above consensus, supporting upside on earnings power and margin profile. Zoetis forecasts strong 2026 profit
• Positive Sentiment: High profitability metrics — Zoetis reported a robust net margin (~28%) and very high return on equity (~57%), which underscores cash-generation ability and supports valuation multiples. MarketBeat Q4 summary
• Neutral Sentiment: Full earnings call transcript and slide deck are available — management provided detail on geographic and product-line performance that investors will parse for forward visibility and execution risk. Earnings call transcript (Yahoo)
• Negative Sentiment: Analysts flagged weakening trends in key segments and questioned the path to sustained growth — concerns center on segment-specific slides that could make it harder to deliver the raised guidance without margin or mix improvements. Analysts question Zoetis’ pathway to growth (Benzinga)
• Negative Sentiment: Market commentary highlights topline pressure in the U.S. and execution risk on growth, which prompted some selling despite the beat and raised targets. Zoetis slips as outlook shows pressure (Seeking Alpha)
• Negative Sentiment: Popular-press coverage frames the reaction as “in the doghouse” — sentiment pieces emphasize that a beat alone may not overcome visible near‑term softness in certain product lines. MSN: Zoetis in the doghouse

Wall Street Analyst Weigh In

Several brokerages recently commented on ZTS. Morgan Stanley set a $160.00 price objective on shares of Zoetis in a research report on Thursday, December 18th. JPMorgan Chase & Co. decreased their price objective on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. Wall Street Zen upgraded Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, January 23rd. Piper Sandler restated a “neutral” rating and set a $135.00 target price (down previously from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. Finally, BTIG Research reaffirmed a “buy” rating and set a $160.00 price target on shares of Zoetis in a report on Wednesday, December 3rd. Five equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Zoetis presently has an average rating of “Hold” and an average target price of $152.45.

Zoetis Stock Down 2.4%

NYSE ZTS opened at $125.58 on Friday. Zoetis Inc. has a 52 week low of $115.25 and a 52 week high of $177.00. The company has a quick ratio of 2.28, a current ratio of 3.64 and a debt-to-equity ratio of 1.31. The company has a market capitalization of $55.34 billion, a P/E ratio of 21.14, a price-to-earnings-growth ratio of 2.22 and a beta of 0.96. The stock’s 50-day moving average price is $124.26 and its 200-day moving average price is $135.72.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. The company had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.36 billion. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The firm’s revenue was up 3.0% compared to the same quarter last year. During the same quarter last year, the business earned $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, equities research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be issued a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s dividend payout ratio (DPR) is 35.69%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.